Valuation: Avalo Therapeutics, Inc.

Market Cap 604M 537M 498M 453M 855M 57.36B 869M 5.99B 2.35B 29.93B 2.27B 2.22B 95.43B P/E 2026 *
-3.97x
P/E 2027 * -4.1x
Enterprise Value 180M 160M 149M 135M 255M 17.12B 259M 1.79B 701M 8.94B 677M 663M 28.48B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.31%
Yield 2026 *
0.1%
Yield 2027 * 0.01%
1 day-6.16%
1 week-17.44%
Current month-26.48%
1 month-32.03%
3 months-36.97%
6 months-21.84%
Current year-37.94%
1 week 11.23
Extreme 11.23
13.69
1 month 11.23
Extreme 11.23
16.92
Current year 11.23
Extreme 11.23
24.27
1 year 11.23
Extreme 11.23
24.27
3 years 3.39
Extreme 3.39
38.04
5 years 3.39
Extreme 3.39
7,055.95
10 years 3.39
Extreme 3.39
22,031.54
Manager TitleAgeSince
Chief Executive Officer 72 14/02/2022
Director of Finance/CFO 42 14/02/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 08/08/2022
Director/Board Member 78 12/10/2020
Director/Board Member 55 28/03/2024
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Free

Director

1,322 0.0025%
30/09/26 Free

Director

1,109 0.0021%
30/09/26 Free

Director

1,352 0.0025%
Change 5-day change 1-year change 3-year change Capi.($)
-6.16%-17.44%-19.50%-70.61% 604M
-6.60%-8.56%+42.79%+64.16% 65B
-4.09%-0.11%+2.31%+54.81% 51.19B
+0.03%+5.56%+10.18%+41.75% 51.2B
-1.53%+2.70%+29.72%+34.13% 43.93B
-1.34%+4.12%+16.05%+112.18% 41.96B
-5.97%-6.22%+258.21%+421.57% 38.14B
+6.53%+8.02%+15.74%+53.94% 33.24B
-0.90%-10.49%+31.48%-1.63% 25.2B
-2.76%-9.54%-16.53%-9.55% 22.03B
Average -2.28%-3.25%+37.04%+70.07% 37.25B
Weighted average by Cap. -2.30%-1.23%+43.46%+88.32%

Financials

2026 *2027 *
Net sales - -
Net income -111M -98.85M -91.62M -83.36M -157M -10.55B -160M -1.1B -432M -5.51B -417M -408M -17.56B -133M -118M -109M -99.33M -187M -12.58B -190M -1.31B -515M -6.56B -497M -487M -20.92B
Net Debt -424M -377M -349M -318M -600M -40.24B -609M -4.2B -1.65B -21B -1.59B -1.56B -66.94B -306M -272M -252M -229M -432M -29B -439M -3.03B -1.19B -15.13B -1.15B -1.12B -48.24B
Projected Income Statement - Annual - Avalo Therapeutics, Inc.
Logo Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Employees
33
Date Price Change Volume
16/10/26 $11.27 -6.16% 971,102
15/10/26 $12.01 +1.44% 936,285
14/10/26 $11.84 -1.42% 1,237,160
13/10/26 $12.01 -9.29% 1,649,096
12/10/26 $13.24 -3.00% 502,773
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Avalo Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
11.27USD
Average target price
44.08USD
Spread / Average Target
+291.16%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Avalo Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. AVTX Stock